ESMO 2014 - TARGET: Second-Line Treatment of Folate-Receptor-Positive NSCLC

Speaker: Raffaele Califano

R. Califano describes the rational and design of the TARGET trial highlighting the need for further research in this setting based on the non-MET primary endpoint (Abstract LBA40_PR at ESMO 2014 Congress).

Discussion points

Califano explains the rational for the study and its design and warns that further research needs to be conducted as the primary endpoint (progression-free survival) were not statistically significant.

Abstract Discussed